These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27396428)

  • 41. Clinical and radiographic effects of ascorbic acid-augmented platelet-rich fibrin versus platelet-rich fibrin alone in intra-osseous defects of stage-III periodontitis patients: a randomized controlled clinical trial.
    Elbehwashy MT; Hosny MM; Elfana A; Nawar A; Fawzy El-Sayed K
    Clin Oral Investig; 2021 Nov; 25(11):6309-6319. PubMed ID: 33842996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of bovine porous bone mineral in combination with enamel matrix proteins or with an autologous fibrinogen/fibronectin system in the treatment of intrabony periodontal defects in humans.
    Lekovic V; Camargo PM; Weinlaender M; Vasilic N; Djordjevic M; Kenney EB
    J Periodontol; 2001 Sep; 72(9):1157-63. PubMed ID: 11577946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of intrabony periodontal defects in controlled diabetic patients with an enamel matrix derivative: a split-mouth randomized clinical trial.
    Cimões R; Santiago LM; de França Caldas Júnior A; de Carvalho Farias Vajgel B; Perussolo J; Donos N
    Clin Oral Investig; 2022 Mar; 26(3):2479-2489. PubMed ID: 34643808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year follow-up of regenerative periodontal therapy with enamel matrix derivative at sites with angular bone defects.
    Heden G; Wennström JL
    J Periodontol; 2006 Feb; 77(2):295-301. PubMed ID: 16460257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Five-year clinical results for treatment of intrabony defects with EMD, guided tissue regeneration and open-flap debridement: a case series.
    Mitani A; Takasu H; Horibe T; Furuta H; Nagasaka T; Aino M; Fukuda M; Fujimura T; Mogi M; Noguchi T
    J Periodontal Res; 2015 Feb; 50(1):123-30. PubMed ID: 24815103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans.
    Sculean A; Barbé G; Chiantella GC; Arweiler NB; Berakdar M; Brecx M
    J Periodontol; 2002 Apr; 73(4):401-8. PubMed ID: 11990441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a synthetic bone graft.
    Hoffmann T; Al-Machot E; Meyle J; Jervøe-Storm PM; Jepsen S
    Clin Oral Investig; 2016 Mar; 20(2):357-64. PubMed ID: 26174080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantification of growth factors in advanced platelet-rich fibrin and concentrated growth factors and their clinical efficacy as adjunctive to the GTR procedure in periodontal intrabony defects.
    Lei L; Yu Y; Han J; Shi D; Sun W; Zhang D; Chen L
    J Periodontol; 2020 Apr; 91(4):462-472. PubMed ID: 31471902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet-Rich Fibrin in Regeneration of Intrabony Defects: A Randomized Controlled Trial.
    Patel GK; Gaekwad SS; Gujjari SK; S C VK
    J Periodontol; 2017 Nov; 88(11):1192-1199. PubMed ID: 28820322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Healing of two and three wall intrabony periodontal defects following treatment with an enamel matrix derivative combined with autogenous bone.
    Yilmaz S; Cakar G; Yildirim B; Sculean A
    J Clin Periodontol; 2010 Jun; 37(6):544-50. PubMed ID: 20507378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and radiographic effects of enamel matrix derivative in the treatment of intrabony periodontal defects: a 12-month longitudinal placebo-controlled clinical trial in adult periodontitis patients.
    Rösing CK; Aass AM; Mavropoulos A; Gjermo P
    J Periodontol; 2005 Jan; 76(1):129-33. PubMed ID: 15830647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Injectable platelet-rich fibrin with demineralized freeze-dried bone allograft compared to demineralized freeze-dried bone allograft in intrabony defects of patients with stage-III periodontitis: a randomized controlled clinical trial.
    Alshoiby MM; Fawzy El-Sayed KM; Elbattawy W; Hosny MM
    Clin Oral Investig; 2023 Jul; 27(7):3457-3467. PubMed ID: 37002441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Periodontal Intrabony Defects Using Enamel Matrix Derivative: Surgical Reentry After an Observation Period of at Least 5 Years.
    Iorio-Siciliano V; Blasi A; Nuzzolo P; Matarasso M; Isola G; Ramaglia L
    Int J Periodontics Restorative Dent; 2019; 39(4):537-543. PubMed ID: 31226192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative evaluation of platelet-rich fibrin and autogenous bone graft for the treatment of infrabony defects in chronic periodontitis: Clinical, radiological, and surgical reentry.
    Galav S; Chandrashekar KT; Mishra R; Tripathi V; Agarwal R; Galav A
    Indian J Dent Res; 2016; 27(5):502-507. PubMed ID: 27966508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multi-centre randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/synthetic bone graft or enamel matrix derivatives alone: results after 12 months.
    Meyle J; Hoffmann T; Topoll H; Heinz B; Al-Machot E; Jervøe-Storm PM; Meiss C; Eickholz P; Jepsen S
    J Clin Periodontol; 2011 Jul; 38(7):652-60. PubMed ID: 21564156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects.
    Guida L; Annunziata M; Belardo S; Farina R; Scabbia A; Trombelli L
    J Periodontol; 2007 Feb; 78(2):231-8. PubMed ID: 17274711
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term stability of adjunctive use of enamel matrix protein derivative on porcine-derived xenograft for the treatment of one-wall intrabony defects: A 4-year extended follow-up of a randomized controlled trial.
    Lee JH; Jeong SN
    J Periodontol; 2022 Feb; 93(2):229-236. PubMed ID: 34050681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of intrabony defects with enamel matrix proteins or bioabsorbable membranes. A 4-year follow-up split-mouth study.
    Sculean A; Donos N; Miliauskaite A; Arweiler N; Brecx M
    J Periodontol; 2001 Dec; 72(12):1695-701. PubMed ID: 11811505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial.
    Sanz M; Tonetti MS; Zabalegui I; Sicilia A; Blanco J; Rebelo H; Rasperini G; Merli M; Cortellini P; Suvan JE
    J Periodontol; 2004 May; 75(5):726-33. PubMed ID: 15212355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical evaluation of an enamel matrix protein derivative combined with either a natural bone mineral or beta-tricalcium phosphate.
    Döri F; Arweiler N; Gera I; Sculean A
    J Periodontol; 2005 Dec; 76(12):2236-43. PubMed ID: 16332235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.